Amphastar Pharma Files 2024 Proxy Statement
Ticker: AMPH · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 1297184
| Field | Detail |
|---|---|
| Company | Amphastar Pharmaceuticals, Inc. (AMPH) |
| Form Type | DEF 14A |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, sec-filing
TL;DR
Amphastar's proxy statement is out, detailing exec pay and equity awards for 2024.
AI Summary
Amphastar Pharmaceuticals, Inc. filed its DEF 14A on April 14, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to PEO and Non-PEO NEO members. Specific values for equity awards granted in the current year and adjustments to the fair value of prior year awards are presented for the fiscal year 2024.
Why It Matters
This filing provides transparency into how Amphastar Pharmaceuticals compensates its top executives, which can influence investor decisions and perceptions of corporate governance.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that provides information on executive compensation and does not indicate any immediate operational or financial risks.
Key Numbers
- 2024 — Fiscal Year (The period for which compensation details are reported.)
- 20250414 — Filing Date (The date Amphastar Pharmaceuticals, Inc. submitted this DEF 14A filing.)
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
- 0001297184-25-000018.txt (document) — Accession number for the filing
- 20250414 (date) — Filing date
- 20250602 (date) — Period of report
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing detailed information on matters to be voted upon, including executive compensation, director elections, and other corporate governance issues.
Who are the key individuals whose compensation is detailed in this filing?
The filing details compensation for PEO (Principal Executive Officer) and Non-PEO NEO (Named Executive Officer) members, as indicated by the tags amph:EquityAwardsValueInCompensationTableForApplicableYearMember ecd:PeoMember and amph:EquityAwardsValueInCompensationTableForApplicableYearMember ecd:NonPeoNeoMember.
What specific types of equity awards are discussed in the filing?
The filing discusses 'Equity Awards Value in Compensation Table' and 'Equity Awards Adjustments Year-End Fair Value of Awards Granted in Current Year' for both PEO and Non-PEO NEO members.
What is the fiscal year end for Amphastar Pharmaceuticals, Inc.?
Amphastar Pharmaceuticals, Inc.'s fiscal year ends on December 31 (1231).
When is the period of report for this DEF 14A filing?
The conformed period of report for this DEF 14A filing is 20250602.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 regarding Amphastar Pharmaceuticals, Inc. (AMPH).